Benzodiazepine use among older adults with chronic obstructive pulmonary disease: A population-based cohort study

Drugs and Aging

Volumn 30, Issue 3, 2013, Pages 183-192

  Vozoris, Nicholas T ^a,c,g   Fischer, Hadas D ^b   Wang, Xuesong ^b   Anderson, Geoffrey M ^b,d,e   Bell, Chaim M ^b,c,d,h   Gershon, Andrea S ^b,c   Stephenson, Anne L ^a,c,f   Gill, Sudeep S ^b,g   Rochon, Paula A ^b,c,d,e  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b Institute for Clinical and Evaluative Sciences   (Canada)

^c UNIVERSITY OF TORONTO   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

^e WOMEN S COLLEGE HOSPITAL   (Canada)

^f ST MICHAEL'S HOSPITAL   (Canada)

^g QUEEN S UNIVERSITY   (Canada)

^h MOUNT SINAI HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; BENZODIAZEPINE; BROMAZEPAM; CHLORDIAZEPOXIDE; CLOBAZAM; CLONAZEPAM; CLORAZEPATE; DIAZEPAM; FLURAZEPAM; LORAZEPAM; NITRAZEPAM; OXAZEPAM; TEMAZEPAM; TRIAZOLAM;

AGED; ARTICLE; CANADA; CHRONIC OBSTRUCTIVE LUNG DISEASE; DISEASE EXACERBATION; DISEASE SEVERITY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PRESCRIPTION; PRIORITY JOURNAL;

EID: 84876938173     PISSN: 1170229X     EISSN: 11791969     Source Type: Journal    
DOI: 10.1007/s40266-013-0056-1     Document Type: Article

References (46)

1. Cohn MA, Morris DD, Juan D. Effects of estazolam and flurazepam on cardiopulmonary function in patients with chronic obstructive pulmonary disease. Drug Saf. 1992;7:152-8.
2. Jolly E, Aguirre L, Jorge E, et al. Acute effect of lorazepam on respiratory muscles in stable patients with chronic obstructive pulmonary disease. [Article in Spanish]. Medicina (B Aires). 1996;56:472-8.
3. Murciano D, Aubier M, Palacios S, et al. Comparison of zolpidem (Z), triazolam (T), and flunitrazepam (F) effects on arterial blood gases and control of breathing in patients with severe chronic obstructive pulmonary disease (COPD). Chest. 1990;97:51S-2S. (Pubitemid 20082290)
4. Murciano D, Armengaud MH, Cramer PH, et al. Acute effects of zolpidem, triazolam and flunitrazepam on arterial blood gases and control of breathing in severe COPD. Eur Respir J. 1993;6:625-9. (Pubitemid 23160257)
5. Rudolf M, Geddes DM, Turner JA, et al. Depression of central respiratory drive by nitrazepam. Thorax. 1978;33:97-100. (Pubitemid 8281620)
6. Block AJ, Dolly FR, Slayton PC. Does flurazepam ingestion affect breathing and oxygenation during sleep in patients with chronic obstructive lung disease? Am Rev Respir Dis. 1984;129:230-3. (Pubitemid 14189160)
7. Beaupré A, Soucy R, Phillips R, et al. Respiratory center output following zopiclone or diazepam administration in patients with pulmonary disease. Respiration. 1988;54:235-40. (Pubitemid 19104675)
8. Berry RB, McCasland CR, Light RW. The effect of triazolam on the arousal response to airway occlusion during sleep in normal subjects. Am J Respir Crit Care Med. 1992;146:1256-560.
9. Celli BR, ATS/ERS Task Force. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932-46. (Pubitemid 38807371)
10. Greenblatt DJ, Shader RI, Harmatz JS. Implications of altered drug disposition in the elderly: studies of benzodiazepines. J Clin Pharmacol. 1989;29:866-72. (Pubitemid 20002697)
11. Greenblatt DJ, Harmatz JS, Shader RI. Clinical pharmacokinetics of anxiolytics and hypnotics in the elderly. Therapeutic considerations (Part I). Clin Pharmacokinet. 1991;21:165-77.
12. Tamblyn RM, McLeod PJ, Abrahamowicz M, et al. Questionable prescribing for elderly patients in Quebec. CMAJ. 1994;150:1801-9. (Pubitemid 24215297)
13. Tu K, Mamdani MM, Hux JE, et al. Progressive trends in the prevalence of benzodiazepine in older people in Ontario, Canada. J Am Geriatr Soc. 2001;49:1341-5. (Pubitemid 33015211)
14. Busto UE, Sproule BA, Knight K, et al. Use of prescription and nonprescription hypnotics in a Canadian elderly population. Can J Clin Pharmacol. 2001;8:213-21. (Pubitemid 34072387)
15. Hogan DB, Maxwell CJ, Fung TS. Prevalence and potential consequences of benzodiazepine use in senior citizens: results from the Canadian Study of Aging and Health. Can J Clin Pharmacol. 2003;10:72-7. (Pubitemid 37028597)
16. Halme AS, Beland SG, Preville M, Tannenbaum C. Uncovering the source of new benzodiazepine prescriptions in community-dwelling older adults. Int J Geriatr Psychiatry. 2012. doi: 10.1002/gps.3818.
17. Simon GE, VonKorff M, Barlow W, et al. Predictors of chronic benzodiazepine use in a health maintenance organization sample. J Clin Epidemiol. 1996;49:1067-73. (Pubitemid 26319043)
18. Magrini N, Vaccheri A, Parma E, et al. Use of benzodiazepines in the Italian general population: prevalence, pattern of use and risk factors for use. Eur J Clin Pharmacol. 1996;50:19-25. (Pubitemid 26141503)
19. Kirby M, Denihan A, Bruce I, et al. Benzodiazepine use among the elderly in the community. Int J Geriatr Psychiatry. 1999;14:280-4. (Pubitemid 29199573)
20. Gleason PP, Schulz R, Smith NL, et al. Correlates and prevalence of benzodiazepine use in community-dwelling elderly. J Gen Intern Med. 1998;13:243-50. (Pubitemid 28169437)
21. Fourrier A, Letenneur L, Dartigues JF, et al. Benzodiazepine use in an elderly community-dwelling population. Characteristics of users and factors associated with subsequent use. Eur J Clin Pharmacol. 2001;57:419-25. (Pubitemid 33787193)
22. Ohayon MM, Lader MH. Use of psychotropic medication in the general population of France, Germany, Italy, and the United Kingdom. J Clin Psychaitry. 2002;63:817-25.
23. Cormick W, Olson LG, Hensley MJ, et al. Nocturnal hypoxaemia and quality of sleep in patients with chronic obstructive lung disease. Thorax. 1986;41:846-54. (Pubitemid 17171682)
24. Klink ME, Quan SF. Prevalence of reported sleep disturbances in a general adult population and their relationship to obstructive airways diseases. Chest. 1987;91:540-6. (Pubitemid 17058876)
25. Klink ME, Dodge R, Quan SF. The relation of sleep complaints to respiratory symptoms in a general population. Chest. 1994;105:151-4. (Pubitemid 24029093)
26. Hill K, Geist R, Goldstein RS, et al. Anxiety and depression in end-stage COPD. Eur Resp J. 2008;31:667-77.
27. Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered questions and research needs. Chest. 2008;134:43S-56S.
28. Marciniuk D, Goodridge D, Hernandez P, Canadian Thoracic Society COPD Committee Dyspnea Expert Working Group, et al. Managing dyspnea in patients with advanced chronic obstructive pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J. 2011;18:69-78.
29. Gershon AS, Wang C, Guan J, et al. Identifying individuals with physician diagnosed COPD in health administrative databases. J COPD. 2009;6:388-94.
30. Levy R, O'Brien BJ, Sellors C, et al. Coding accuracy of administrative drug claims in the Ontario Drug Benefit database. Can J Pharmacol. 2003;10:67-71. (Pubitemid 37028596)
31. Donaldson GC, Seemungal TA, Bhowmik A, et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax. 2002;57:847-52. (Pubitemid 35178607)
32. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J Med. 2010;363:1128-38.
33. Connors AF Jr, Dawson NV, Thomas C, et al. Outcomes following acute exacerbation of severe chronic obstructive lung disease. The SUPPORT investigators (Study to Understand Prognoses and Preferences for Outcomes and Risks of Treatments). Am J Respir Crit Care Med. 1996;154:959-67.
34. Miravitlles M, Guerrero T, Mayordomo C, et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. The EOLO Study Group. Respiration. 2000;67:495-501.
35. O'Donnell DE, Hernandez P, Kaplan A, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2008 update: highlights for primary care. Can Resp J. 2008;15S:1A-8A. (Pubitemid 351566057)
36. Canadian Pharmacists Association. Compendium of pharmaceuticals and specialties. Ottawa: The Canadian Drug Reference for Health Professionals. Canadian Pharmacists Association; 2008.
37. Rochon PA, Normand SL, Gomes T, et al. Antipsychotic therapy and short-term serious events in older adults with dementia. Arch Inter Med. 2008;168:1090-6.
38. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2011. http://www.goldcopd.org.
39. Vozoris NT, Leung RS. Sedative medication use: prevalence, risk factors, and associations with body mass index using population-level data. Sleep. 2011;34:869-74.
40. Woolcott JC, Richardson KJ, Wiens MO, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Arch Int Med. 2009;169:1952-60.
41. Glass J, Lanctôt KL, Herrmann N, et al. Sedative hypnotics in older people with insomnia: meta-analysis of risks and benefits. BMJ. 2005;331:1169-76. (Pubitemid 41689427)
42. Barbone F, McMahon AD, Davey PG, et al. Association of road-traffic accidents with benzodiazepine use. Lancet. 1998;352:1331-6. (Pubitemid 28510912)
43. The American Geriatrics Society 2012 Beers Criteria Expert Panel. American Geriatrics Society updated Beers criteria for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2012;60:616-31.
44. Hemmelgarn B, Suissa S, Huang A, et al. Benzodiazepine use and the risk of motor vehicle crash in the elderly. JAMA. 1997;278:27-31. (Pubitemid 27274512)
45. Ray WA, Griffin MR, Downey W. Benzodiazepines of long and short elimination half-life and the risk of hip fracture. JAMA. 1989;262:3303-7. (Pubitemid 20012552)
46. Bell CM, Fischer HD, Gill SS, et al. Initiation of benzodiazepines in the elderly after hospitalization. J Gen Intern Med. 2007;22:1024-9. (Pubitemid 46878604)